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grams), and male gender. Increasing length of mechanical ventilation and birth 
weight 500-999 grams were associated with ever receiving inhaled 
corticosteroids. CONCLUSIONS: Bronchodilator and ICS use are common for 
infants with BPD at U.S. Children's hospitals, although frequency of use varies 
significantly. The effectiveness and safety of their use in these infants needs to 
be determined, in order to develop evidence-based recommendations.  
 
PIH50  
EFFECTS OF ETHNICITY ON CAREGIVER BURDEN, SELF-EFFICACY, AND 
QUALITY OF LIFE AMONG WORKING CAREGIVERS OF OLDER ADULTS  
Branin J1, Juarez G2 
1University of La Verne, La Verne, CA, USA, 2City of Hope, Duarte, CA, USA  
OBJECTIVES: Research has shown that employees caring for older adults may 
experience physiological and psychosocial effects and require family supports 
that may vary across different ethnic groups. The purpose of this study was to 
explore differences in caregiving skills; caregiver burden; self-efficacy; and 
quality of life, health and well-being of African-American and Caucasian 
caregivers who are providing care for an older adult. METHODS: A total of 153 
Caucasian and African-American adults currently working and caring for an 
older adult were personally interviewed. RESULTS: The typical working caregiver 
was a 49-year-old woman caring for her 79-year-old mother with African-
American caregivers more likely to be living in the same household. In the past 
six months, African-American caregivers were more likely to have taken off 
work more than twenty hours and used the telephone at work one to five times a 
week for caregiving responsibilities. Caregiver Self Efficacy was positively related 
to Caregiver Rewards (r=.424, p<0.001) and negatively related to Burden (r=-0.310, 
p<0.001) for both groups. Regarding Caregiving Skills, African-American 
caregivers rated their skills in communicating with their older loved one more 
highly than Caucasian (beta=.332, p<0.001) and were more likely to have taken 
more than 20 hours off work (beta =0.201, p<0.05). African-American caregivers 
were less confident of finding information and good resources for their elder 
care recipient and themselves than Caucasian caregivers (beta = -0.175, p<0.05 
and beta = -0.183, p<0.05 respectively). Those caregivers with greater self-efficacy 
and greater caregiver rewards reported greater quality of life. There were 
significant differences in caregiver burden with African-Americans feeling a 
greater level of burden. CONCLUSIONS: The differing effects of elder caregiving 
among African-Americans and Caucasian caregivers may require different, more 
personalized caregiver interventions and supports to reduce the caregiver 
burden, increase feelings of rewards, and improve the quality of life for both 
ethnic groups.  
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MATCHING-ADJUSTED INDIRECT COMPARISON OF LIPID PROFILE AT 48 WEEKS 
AMONG TREATMENT NAÏVE HIV-1 PATIENTS TREATED WITH 
ATAZANAVIR/RITONAVIR VERSUS DARUNAVIR/RITONAVIR  
Xie J1, Juday TR2, Swallow E3, Du X3, Uy J2, Hebden T4, Signorovitch J3 
1Analysis Group, Inc., New York, NY, USA, 2Bristol-Myers Squibb Company, Plainsboro, NJ, USA, 
3Analysis Group, Inc., Boston, MA, USA, 4Bristol-Myers Squibb, Plainsboro, NJ, USA  
OBJECTIVES: This study estimates lipid profile changes and abnormalities in 
treatment naïve HIV patients initiating atazanavir/ritonavir (ATV/r) versus 
darunavir/ritonavir (DRV/r) using a matched indirect comparison. METHODS: 
Two similarly designed randomized trials were identified. Individual patient-
level data were available for the CASTLE trial comparing ATV/r (n=430) and 
lopinavir/r (LPV/r) (n=438); published summary data were used from the 
ARTEMIS trial comparing DRV/r (n=343) and LPV/r (n=346). To adjust for cross-
trial differences, CASTLE patients were re-weighted to match summary baseline 
characteristics in ARTEMIS. Lipid profile changes and serious (grade 2-4) lipid 
laboratory abnormalities (LA) at 48 weeks were compared between balanced trial 
populations after matching. If significant differences in LPV/r outcomes existed 
after matching, the differences between active treatments and LPV/r were 
compared across trials. RESULTS: Data from all patients in the two trials were 
included. Before matching, CASTLE patients at baseline had a higher proportion 
of HIV-1 RNA>100,000 copies/mL, a lower proportion CDC class C, and lower 
median CD4 cell count than ARTEMIS patients. An unadjusted cross-trial 
comparison at 48 weeks showed that ATV/r and DRV/r had similar changes in 
total cholesterol, low density lipoprotein (LDL), and triglycerides, but ATV/r had 
significantly lower rates of total cholesterol LA (7% vs.13%, p=0.008) and LDL LA 
(8% vs. 13%, p=0.040). After balancing mean baseline characteristics, ATV/r and 
DRV/r at 48 weeks had similar changes in total cholesterol, LDL, and triglycerides 
(adjusted difference [AD]= -7.19, -7.11 and 7.59 mg/dL, respectively) and similar 
percentages of grade 2-4 triglycerides and cholesterol LAs (AD=0% and 1%, 
respectively); however, ATV/r had a significantly lower rate of serious LDL LA 
(AD=-9%, p=0.006). CONCLUSIONS: While the overall lipid profiles of ATV/r and 
DRV/r were similar at 48 weeks in this matching-adjusted indirect comparison, 
ATV/r had a significantly lower rate of serious LDL LA.  
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THE IMPACT OF CLOSTRIDIUM DIFFICILE INFECTION ON MEDICARE 
BENEFICIARY HEALTH CARE UTILIZATION AND OUTCOMES  
Drozd EM1, Hemal S2, Thomas SM2, Braithwaite SF1 
1Avalere Health, LLC, Washington, DC, USA, 2Optimer Pharmaceuticals, Inc., Jersey City, NJ, 
USA  
OBJECTIVES: Clostridium difficile infection (CDI) primarily occurs in elderly 
adults and contributes to excess patient mortality, readmissions, hospital costs, 
and post-discharge costs. Two-thirds of CDI hospitalizations are for patients 
with CDI as a secondary diagnosis (“secondary CDI”). This study assesses the 
burden of illness of secondary CDI on outcomes and healthcare utilization for 
hospitalized Medicare beneficiaries. METHODS: Using a 5% random sample of 
Medicare claims from 2009–2010, patients with and without secondary CDI and 
no prior hospitalization within the previous 30 days were identified. Prior year 
claims data were used to describe case mix and baseline characteristics. 
Propensity scores were developed to match CDI and non-CDI patients on 
potential confounding factors. Outcomes of interest were: index episode length-
of-stay (LOS), emergency department (ED) and ICU use, inpatient mortality, post-
discharge mortality, readmissions, and acute care use. RESULTS: The final 
sample size after a propensity score match was 3262 patients in each patient 
cohort. Secondary CDI was associated with an 80% increase in hospital LOS, and 
a greater than 160% increase in ICU days, relative to patients without CDI. 
Secondary CDI was associated with an 80% increase in both inpatient and 30-day 
post-discharge mortality. Inpatient mortality for immunocompromized patients 
was 130% greater than like patients without CDI. Secondary CDI was associated 
with a 41% increase in 30-day CDI readmission rates and a 46% increase in the 
number of readmissions per admission. Immunocompromised patients with 
secondary CDI were associated with a 180% increase in post-discharge CDI-
related ED visits and a 65% increase in post-discharge skilled nursing facility 
admissions. CONCLUSIONS: Secondary CDI in hospitalized Medicare 
beneficiaries is associated with considerable negative impacts on LOS, mortality, 
readmission rates, and post-discharge utilization compared to matched controls. 
Consequently, comprehensive CDI prevention and treatment strategies are 
needed to decrease resource utilization and burden in patients who develop 
secondary CDI.  
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USING CLAIMS DATA FOR SURGICAL SITE INFECTION SURVEILLANCE AFTER 
HERNIORRHAPHY  
Mines D1, Nickel KB2, Wallace AE1, Warren DK2, Olsen MA2 
1HealthCore, Inc, Wilmington, DE, USA, 2Washington University School of Medicine, St. Louis, 
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OBJECTIVES: Billing and claims data can potentially be used to identify surgical 
site infections (SSIs) for quality improvement initiatives. We investigated the 
effect that variation in procedure coding by providers and facilities has on the 
calculated SSI incidence. METHODS: We established a retrospective cohort study 
of individuals aged 6 months – 64 years with ICD-9-CM procedure or CPT-4® 
codes from facility and/or provider claims for umbilical, femoral/inguinal, or 
incisional/ventral herniorrhaphy from 1/1/2004-12/31/2010 using private insurer 
claims data. SSIs within 90 days were identified by ICD-9-CM diagnosis codes, 
with censoring for other surgeries within 90 days. Complex surgeries with 
additional procedures performed on or before the herniorrhaphy date during a 
hospitalization were excluded. RESULTS: 155,748 non-complex herniorrhaphy 
procedures were initially identified based on distinct procedure dates >7 days 
apart. The number of distinct procedures was reduced to 144,220 after removing 
procedures with no supportive evidence for operation (e.g., anesthesia, operating 
room revenue codes, pathology; n=4,609) and surgeries coded for >1 hernia site 
or unclassified (n=6,919). The percentage of procedures complicated by SSI was 
compared according to the stringency of identification of hernia site. Using all 
claims coded for herniorrhaphy (facility and/or provider), 1.23% (363/29,582) of 
umbilical, 0.48% (433/90,231) of femoral/inguinal, and 4.00% (976/24,407) of 
incisional/ventral procedures were complicated by SSI within 90 days. In 
contrast, the percentages of procedures complicated by SSI were 1.17% 
(297/25,323) for umbilical, 0.46% (367/79,063) for femoral/inguinal, and 4.18% 
(752/17,981) for incisional/ventral herniorrhaphy when agreement between the 
provider and facility procedure coding was required to define the hernia site. 
CONCLUSIONS: Use of claims data to determine SSI rates requires careful 
classification of procedures, particularly when characteristics of the surgical 
procedure are important risk factors for infection.  
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HOSPITALIZATION AMONG VETERANS  
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OBJECTIVES: Multiple sclerosis (MS) is characterized by autoimmune mediated 
demyelination of the central nervous system, and affects nearly 300,000 
individuals in the United States (US). Immunosuppressive MS therapy often 
leads to infections, which in turn may cause relapse or exacerbation of MS 
symptoms. This study is the first to evaluate the magnitude of the association 
between MS and serious infections in a US population. METHODS: Adult patients 
with MS, within the US Veterans Health Administration (VHA) system from 1999-
2010 were identified. Those without encounters 6 months or more before the 
first diagnosis were excluded. Each MS patient was matched, on age and sex, 
with up to 4 non-MS patients. Cox Proportional Hazards regression models were 
developed to assess the influence of MS on serious infections identified by ICD-9 
code. An infection was considered serious when listed as a hospital admission 
diagnosis in the VHA inpatient setting. Our regression models controlled for 
patient demographic characteristics, comorbid conditions, drug exposures, 
disability status, and health care utilization. RESULTS: Our analysis cohort 
consisted of 7,743 MS and 30,972 non-MS patients. Mean age was 53.8 (SD 13.4) 
years and 80.7% were male. Race was known in 40.8%; of which 80.2% were 
white, 16.0% black, and 3.8% variant ethnicities. The incidence of overall serious 
infections was 18.7 (95% CI=17.2-20.3) and 10.0 (95% CI=9.5-10.6) per 1,000 
person-years for MS and non-MS patients, respectively. Regression models 
revealed that MS patients were at greater risk for overall serious infections 
(HR=1.54, p<0.001) as well as serious respiratory (HR=1.31, p=0.01), urinary tract 
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(HR=4.46, p<0.001), and sepsis-related infections (HR=2.76, p<0.001) while 
controlling for other patient characteristics. CONCLUSIONS: This study provides 
evidence that VHA patients with MS are more likely than non-MS patients to be 
hospitalized due to infection. Efforts to reduce these complications may improve 
patient health while lowering health care costs.  
 
PIN5  
EVALUATION OF THE CLINICAL AND ECONOMIC BURDEN OF THE HUMAN 
IMMUNODEFICIENCY VIRUS IN VETERAN PATIENTS IN THE UNITED STATES  
Wang L1, Zhang J1, Baser O2 
1STATinMED Research, Dallas, TX, USA, 2STATinMED Research/The University of Michigan, 
Ann Arbor, MI, USA  
OBJECTIVES: To assess the clinical characteristics, utilization, and cost patterns 
of human immunodeficiency virus (HIV) patients in the U.S. veteran population. 
METHODS: A retrospective analysis was performed using the Veterans Health 
Administration (VHA) Medical SAS Datasets from October 1, 2005 to May 31, 2012. 
All U.S. veteran beneficiaries diagnosed with HIV were identified using 
International Classification of Disease 9th Revision Clinical Modification (ICD-9-
CM) diagnosis codes 042.xx and V08.xx. Descriptive statistics were calculated as 
means ± standard deviation (SD) and percentages to measure comorbidities, 
cost, and utilization distribution in the sample. Health care resource utilization 
and costs were assessed for the 12-month follow-up period. Clinical status and 
laboratory tests were examined for the 12-month baseline period before disease 
identification. RESULTS: A total of 10,873 patients were diagnosed with HIV from 
2006 to 2011 in the U.S. veteran population. Common comorbidities included 
hypertension (n=1,047, 9.63%), depressive disorder (n=590, 5.43%) and diabetes 
mellitus (n=499, 4.59%). Outpatient services were utilized by 99.77% of  
HIV patients, followed by pharmacy visits (89.70%) and inpatient visits (27.67%). 
Costs for outpatient ($13,338, SD=$15,709), pharmacy ($5,345, SD=$8,593) and 
inpatient services ($12,072, SD=$45,507) contributed to follow-up health care 
expenditures. The top three treatments for U.S. veteran HIV patients  
were sulfamethoxazole/trimethoprim, efavirenz/emtricitabine/tenofovir, and 
emtricitabine/tenofovir. Among 10,873 HIV patients, a total of 1,295 (11.91%) had 
CD-4 tests, of which 142 patients had values ≤50. A total of 847 patients (7.79%) 
had the HIV viral load test, of which 194 patients had values >100,000. 
CONCLUSIONS: Sulfamethoxazole/trimethoprim, efavirenz/emtricitabine/ 
tenofovir, and emtricitabine/tenofovir were the most frequently prescribed  
HIV medications. More research is required to better understand the  




EPIDEMIOLOGY AND COSTS OF MENINGOCOCCAL DISEASE IN BRAZIL:  
A SURVEY OF THE LITERATURE  
Carpiuc KT1, Snedecor SJ1, Roberts CS2, Fujii RK3 
1Pharmerit International, Bethesda, MD, USA, 2Pfizer, New York, NY, USA, 3Pfizer, Inc.,  
São Paulo, Brazil  
OBJECTIVES: To review the epidemiology and economic burden of 
meningococcal disease (MD) in Brazil. METHODS: A literature review was 
conducted to identify epidemiologic and economic data on MD and subsequent 
sequelae. Terms “meningitis,” “meningococcal vaccines,” “meningococcal 
disease,” “Neisseria meningitidis,” and “Brazil” with “cost OR econ*” were used to 
search Medline. Supplemental data from internet searches, article references, 
and other Latin American countries were also reviewed. RESULTS: In 2009, Brazil 
had 19,708 confirmed cases of meningitis, of which 6,981 (35.4%) were bacterial. 
Of these, 2,603 (37.3%) were MD. There has been a downward trend in the 
incidence of MD over the last 15 years, which has stabilized to <2 cases/100,000 
population in recent years. The incidence is highest in children <5 years, ranging 
from 10.1 cases/100,000 in infants <1 year to 4.1 cases/100,000 in children 1-4 
years. The case fatality rate for MD is high compared to others worldwide (~20% 
vs.10%). The cost burden of bacterial meningitis and disease sequelae has been 
estimated to comprise direct costs of medical visits, hospital admissions, 
laboratory tests, imaging studies, medications, and transportation to health 
services, as well as costs of work loss from the caregiver. Few studies reported 
direct costs of an MD episode, which ranged from (R$1,000-1,500) in children <9 
years. Corresponding data of costs for MD in adults were not found. Costs of 
sequelae were estimated to be highest for neurological impairment (R$8,053 and 
R$19,154 with indirect costs; 2006 BRL). Data on carriage prevalence rates of N 
meningitidis, the causative agent of MD, were unavailable from Brazil. 
CONCLUSIONS: With active surveillance in Brazil where MD is endemic, 
epidemiology data is robust, but detailed information on the economic burden is 
limited. Carriage rates of N meningitidis are poorly documented in Brazil, which is 




A SYSTEMATIC REVIEW OF DIAGNOSTIC ACCURACY OF FDG PET/PET-CT FOR 
FEVER OF UNKNOWN ORIGIN  
Lee DH1, Park DA1, Lee NR1, Kwak S1, Lee YK1, Park S2, Park Y3, Paeng J4 
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OBJECTIVES: Fever of unknown origin (FUO) is defined as temperature > 101°F on 
several occasions duration of fever of more than 3 weeks and failure to reach to 
diagnosis despite one week of inpatient investigations. This study aimed to 
perform a systematic review to examine the overall diagnostic performance of 
FDG-PET/PET CT in identifying the causal source of FUO. METHODS: We 
searched potentially relevant studies using electronic databases such as Ovid-
Medline, Ovid-EMBASE, Cochrane library, KoreaMed, and Kmbase from their 
inception to May, 2012. Two independent reviewers extracted data using a 
standardized form. The quality of the selected studies was assessed using 
QUADAS-2. A bivariate random model was constructed to summarize the 
sensitivity, specificity and area under the curve (AUC). RESULTS: A total of 15 
studies representing 592 patients were eligible for inclusion. Overall, the studies 
had ‘poor’ methodological quality. Concerns about applicability are rated as 
‘low’. AUC of 6 FDG-PET studies was 0.7955, and the pooled diagnostic odds ratio 
(DOR) was 9.38 (95% CI 1.44-60.91). Pooled sensitivity was 0.859 (95% CI 0.729-
0.932), and the pooled specificity was 0.664 (95% CI 0.416-0.845). As the results of 
meta-regression in accordance with the absence of blinding that causes 
heterogeneity, pooled specificity was significant difference (blinding 0.816, non-
blinding/unclear 0.344, P=0.013). AUC of 9 FDG PET-CT studies was 0.8071, and 
the pooled DOR was 10.93 (95% CI 4.67-25.57). Pooled sensitivity was 0.838 (95% CI 
0.715-0.914), and the pooled specificity was 0.714(95% CI 0.588-0.814). 
CONCLUSIONS: FDG PET/PET-CT test appeared to have a high sensitivity and a 
moderate specificity for the detection of the causes of FUO. However, since a 
limited number of studies are available and included studies were 
heterogeneous with respect to the aspect of study design, the method of 




EFFICACY AND SAFETY OF TELAPREVIR AND BOCEPREVIR IN PATIENTS WITH 
HEPATITIS C GENOTYPE 1: A META-ANALYSIS  
Park C, Jiang S, Lawson KA 
The University of Texas at Austin, Austin, TX, USA  
OBJECTIVES: Two NS3/4A protease inhibitors (PIs), telaprevir and boceprevir, 
were recently approved in the United States. Even though several randomized 
controlled trials (RCTs) have demonstrated the efficacy and safety of PIs, a meta-
analysis using various subgroup analyses based on patient characteristics has 
not been conducted. The objectives were to compare the efficacy and safety of 
these PIs in patients with chronic hepatitis C genotype 1, based on PI type and 
patient characteristics. METHODS: Both published and unpublished RCTs were 
selected if they: 1) compared triple therapies (telaprevir or boceprevir + peg-
interferon + ribavirin) and dual therapy (peg-interferon + ribavirin); 2) had 
treatment groups that met FDA-approved dosages; and 3) measured the outcome 
using sustained virologic response (SVR). RESULTS: A total of 4421 patients from 
10 evaluated articles were included in the meta-analysis. Overall, triple therapy 
was significantly associated with a higher achievement of SVR than dual therapy 
(odds ratio [OR] = 3.959; 95% confidence interval [CI], 3.146 to 4.981). When 
administering triple therapy, the likelihood of achieving SVR in telaprevir-
treated patients (OR = 4.292; 95% CI, 2.893 to 6.369) was significantly different 
than that in boceprevir-treated patients (OR = 3.634; 95% CI, 2.777 to 4.754). The 
likelihood of achieving SVR with triple therapy compared to dual therapy was 
statistically significantly higher in treatment-experienced patients (OR = 7.544; 
95% CI, 5.919 to 9.615) compared to treatment-naïve patients (OR = 3.026; 95% CI, 
2.641 to 3.466). Patients on triple therapies had an increased incidence of 
treatment discontinuation attributable to adverse events when compared with 
the dual therapy, regardless of PI type and patients’ treatment experience. 
CONCLUSIONS: Regarding achieving SVR, triple therapies including either PI are 




EFFECTIVENESS OF THE MONOVALENT ROTAVIRUS VACCINE IN COLOMBIA 
THROUGH DIFFERENT ANALYSES WITHIN AN ECOLOGICAL STUDY  
Paternina-Caicedo A1, Alvis-Guzmán N1, Alvis-Zakzuk N1, Carrasquilla-Sotomayor M1,  
De la Hoz-Restrepo F2 
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Bogota, Colombia  
OBJECTIVES: Monovalent rotavirus vaccine (MNV) was introduced in 2009 in 
Colombia. Despite ecological studies are a major tool in epidemiology, bias may 
influence them. The aim of this study is to assess the effectiveness of the MNV 
in Colombia through several analyses within an ecological study. METHODS: 
Data was collected from the Colombian national statistical agency (DANE) from 
1999-2010 for diarrhea deaths and population under-1 year old. This study made 
the following analyses: 1) Incidence rate ratios (IRR) for regions (states), with 
MNV coverage <50% as reference (low vaccination coverage) and >75% as high 
vaccination coverage; 2) Negative binomial regression pre and post vaccination 
in low and high coverage states; and 3) a longitudinal panel data analysis by 
states of Colombia. RESULTS: 1) As the vaccination coverage increased, the 
reduction of diarrhea-related infant mortality was greater (R-square=0.41). Death 
rate was lower in states with higher coverage in the post vaccination period 
(77.25 deaths per 100,000 people versus 18.31 deaths per 100,000 people); 2) 
Prevaccination trend (1999-2008) of diarrhea-related mortality was between -5.7% 
(95%CI, -0.87% -10.36%) for low coverage states to -9.43% (95%CI, -6.7 – -12.08) for 
high coverage states, and postvaccination trends (2009-2010) were -8.83% (95%CI, 
33.94 to -37.94) for low coverage states and -37.46% (95%CI, -15.34 – -53.8) for high 
coverage states; 3) Multivariable panel regression showed that for each percent 
point the MNV coverage increased, the diarrhea-related mortality decreased by -
0.9% (95%CI, -0.6% – -1.1%). CONCLUSIONS: The post vaccination decrease of 
diarrhea-related infant mortality was robust to changes in analysis. Even further, 
our results strongly suggest better vaccine coverage may be needed for a greater 
MNV vaccine effectiveness.  
